AI uncovers the data behind Novo's Parkinson's stem-cell program
After Novo Nordisk shuttered its cell-therapy unit, Cellular Intelligence hired neurologist Nuno Mendonça to perform due diligence on Novo’s Parkinson’s stem-cell program. The data trail—drawn from Lund University research and Nature Medicine–published work on dopamine-neuron therapies—appears to have driven the AI-driven assessment that led the firm to pursue Novo’s asset.
